Treatment outcomes and cost comparisons for older adults with T4 laryngeal squamous cell cancer

alexandrossfakianakis shared this article with you from Inoreader Treatment outcomes and cost comparisons for older adults with T4 laryngeal squamous cell cancer via Head & Neck Abstract Background To evaluate treatment modalities of T4 larynx cancer in older adults using SEER-Medicare. Methods The database was queried for patients aged 66 and older with nonmetastatic T4 laryngeal squamous cell cancer from 2006 to 2015. Treatment modalities compared were surgery plus chemoradiation (SCR), surgery plus radiation (SR), chemoradiation (CR), surgery (S), and radiation (R). Multivariate analysis and Kaplan–Meier methods were used to explore the relationship of treatment modality and survival. Total cancer-related costs were calculated. Results A total of 438 patients met inclusion criteria. Patients receiving CR or SR had similar CSS to SCR (HR 1.36 and HR 1.24, respectively). Those receiving S (HR 2.00) or R (HR 2.41) had significantly worse CSS. Similar findings were observed for OS. Cancer care-related costs were not significantly different but highest in SCR ($162215) and lowest in R ($121421). Conclusion Older patients with T4 larynx cancer had similar survival rates when treated with CR, SR, and SCR. Average total health care costs were not significantly different between modalities. Patients not eligible for triple-modality could consider these other treatment options. View on Web

Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.